Valuation: SpectraCure AB

Market Cap 10.5M 1.06M 929K 877K 800K 1.5M 101M 1.51M 4.07M 51.84M 3.97M 3.89M 167M P/E 2024
-10.6x
P/E 2025 -0.79x
Enterprise Value -237K -23.89K -20.96K -19.8K -18.04K -33.77K -2.29M -34.01K -91.76K -1.17M -89.69K -87.75K -3.76M EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
28.24%
Yield 2024 *
-
Yield 2025 -
1 week-9.36%
Current month-19.30%
1 month-47.88%
3 months-57.31%
6 months-79.51%
Current year-88.19%
1 week 0.02
Extreme 0.0172
0.02
1 month 0.02
Extreme 0.0172
0.03
Current year 0.02
Extreme 0.0172
0.17
1 year 0.02
Extreme 0.0172
0.24
3 years 0.02
Extreme 0.0172
5.44
5 years 0.02
Extreme 0.0172
10.98
10 years 0.02
Extreme 0.0172
45.15
Manager TitleAgeSince
Chief Executive Officer 54 30/09/2025
Director of Finance/CFO - 31/05/2026
Chief Tech/Sci/R&D Officer - 06/10/2025
Director TitleAgeSince
Director/Board Member 63 30/08/2012
Director/Board Member 72 31/12/2021
Chairman 74 31/12/2021
Date Insider Type Main position Quantity % Market Cap. Importance
26/05/23 Buy

Chairman

25,000 0.0257%
30/08/22 Buy

Director

25,000 0.0257%
09/07/22 Sell

Director

1,048,493 1.0795%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-9.36%-91.50%-99.51% 1.06M
+0.06%-3.26%+44.09%+81.31% 1.44B
-2.35%-6.73%-18.50%-43.17% 50.35M
Average -0.76%-6.45%-21.97%-20.45% 496.03M
Weighted average by Cap. -0.02%-3.38%+41.87%+76.97%

Financials

2024 2025
Net sales - -
Net income -23M -2.32M -2.04M -1.92M -1.75M -3.28M -222M -3.3M -8.91M -114M -8.71M -8.52M -365M -56.08M -5.65M -4.96M -4.69M -4.27M -7.99M -542M -8.05M -21.72M -277M -21.23M -20.77M -890M
Net Debt -13.13M -1.32M -1.16M -1.1M -1M -1.87M -127M -1.89M -5.09M -64.82M -4.97M -4.86M -208M -10.74M -1.08M -950K -897K -818K -1.53M -104M -1.54M -4.16M -53.01M -4.06M -3.98M -170M
Logo SpectraCure AB
SpectraCure AB (publ) is a Sweden-based company, which is primarily engaged in the healthcare industry. The Company specializes in cancer treatment technology. The Company develops photodynamic therapeutics based on photosensitive materials activated by laser. The Company's method is called interstitial photodynamic therapy (PDT). Interstitial PDT can be used for solid tumors in internal organs, such as cancer in the prostate, pancreas, and the head and neck area, among others. In addition, the Company offers software platform IDOSE for interstitial PDT treatment of solid cancer tumors in internal organs. With SpectraCure’s interstitial PDT method, the patient is given a photoactivated drug - photosensitizer in combination with laser light guided by a dose control system.
Employees
13
Date Price Change Volume
25/09/26 SEK 0.0184 0.00% 8,935,229
24/09/26 SEK 0.0184 +1.10% 6,226,132
23/09/26 SEK 0.0182 -2.67% 3,116,789
22/09/26 SEK 0.0187 -1.58% 3,188,659
21/09/26 SEK 0.0190 -6.40% 15,142,587
  1. Stock Market
  2. Stocks
  3. SPEC Stock